Tag Archives: drugs

Politics Law Society

Multi-Billion Euro Corruption Scandal in the EU

Germany and the European Commission collusion to supress a medical device that will save billions on asthma drugs

Multi-Billion Euro Corruption Scandal in the EU

The new non-fiction book „European Politics on Drugs“ from Christoph Klein (Source: Copyright Photographer: Stephan Haeger, Deltawerk)

„There seems to be no limits to their greed and they are doing this to a technology that has proven health benefits, continuing to keep it out of the hands of everyone suffering from asthma and COPD worldwide … If I had explained these events without mentioning Germany and the EU, most people would think I was describing some banana republic or total-itarian regime in the third world.“ – Christoph Klein

About the author: In the early 1990s, Christoph Klein developed an improved inhaler actuator for asthma sprays that realized tremendous savings on pharmaceutical drugs. After the initial excitement surrounding his invention subsided, the device was soon denounced as dangerous (but never any proof) by the pharma industry and the German authorities followed suit. Banned in 1997 with the active support of the European Commission, Germany, and Upper Bavaria in particular, these authorities have succeeded in keeping this effective medical device off of the global market for over two decades.

In 2012, the European Parliament estimated that the ban on Klein“s inhaler had already cost European health insurance programs and their contributors approximately 50 billion euros.

Christoph Klein was born near Cologne, Germany, in 1966. Inventor, entrepreneur, consultant and asthma sufferer himself, Klein has invented several innovative devices to help in the treatment of asthma and COPD. Fighting for justice in courtrooms across Europe for over 20 years, he lives with his wife and two children near Salzburg, Austria.

The Book: European Politics on Drugs is a memoir based on the ongoing scandal known as the „atmed Affair,“ coined by the former Portuguese European Commission President Jose Manuel Barroso in 2007. It is the story of how a seemingly innocent sales ban over public health concerns in Bavaria has prevented a simple invention from gaining access to world-wide markets. A real-life economic thriller that is far from over, the scandal continues to reveal the ugly truths hidden in the EU system. In recounting his 25-year Odyssey, Klein documents a dysfunctional EU, exposing the blatant corruption at its core.

With Brexit and a trade war looming with the United States, Europe is currently facing an existential crisis. People are starting to realize that the power centred in Brussels has become an uncontrollable monstrosity and is largely dominated by German economic interests. In the background, a growing EU political elite, determined to wield its influence over Europe“s destiny, is increasingly acting without regard for the national sovereignty of EU member states and their elected leaders. While serving large economic interests by defending industrial monopolies, the EU is also pursuing a policy of protectionism that is ultimately undermining the rule of law. This is manifested in the manipulation of global trade, where investment security and legal certainty have become anything but certain. Slowly but surely, the European Union is betraying its own raison d“etre.

The new non-fiction book „European Politics on Drugs“ ist now avaible at Amazon

Christoph Klein ist freier Autor, Erfinder, Unternehmer und Berater aus Grossgmain, Österreich

Christoph Klein
Christoph Klein
Poststraße 62
5084 Großgmain
Phone: +49 163 5453849
E-Mail: contact@christoph-klein.info
Url: https://www.christoph-klein.info

Medizin Gesundheit Wellness

Malaysia’s cutting edge products and outsourcing services at CPhI

Malaysia continues to push hard to strengthen its presence in the EU’s Euro 225 billion plus import market.


Malaysian booth at the CPhI 2013

TUESDAY, OCTOBER 22, FRANKFURT: A total of 10 Malaysian exhibitors will be taking part at the CPhi 2013 trade fair at Frankfurt. Malaysia’s pavilion will be in Hall 4.0 D24 and is organised by the Malaysian Ministry of Health and Malaysia External Trade Development Corporation (MATRADE).

According to S. Jai Shankar, the Trade Commissioner at MATRADE’s Frankfurt office, Malaysian pharmaceutical industry has moved up the value chain over the last decade. According to him currently the industry has the capacity to produce medicines in all dosage forms e.g. tablets (coated & non-coated), capsules (hard and soft gelatine), liquids, creams, ointments, sterile eye drops, small volume injectable (ampoules and vials), large volume infusions, dry powders for reconstitution and active pharmaceutical ingredients (API).

Local manufacturers have also developed and launched off-patent generics and herbal products using their own brands. Currently, the local industry is producing about 30 per cent of the domestic demand, as well as exporting to the Asia-Pacific Rim countries, the Middle East, Africa, Latin America and Europe. Leading Malaysian companies are also moving into the production of biologics drugs, oncology and high value-added generic compounds in-line with the growing demands in this region. 246 pharmaceutical premises with Good Manufacturing Practices certification have registered with the Malaysia“s Drug Control Authority (DCA).

According to Mr. Shankar, of these, a total of 51 premises are licensed to produce modern medicines comprising mainly analgesics, antacids, anti-hypertensive, diuretics, antibiotics and anti-histamines in the form of tablets, capsules, drops, powders, creams, ointments, injectable, syrups, ophthalmic and nasal preparations. The remaining 172 premises are licensed to produce local traditional and herbal medicines.

„Malaysia is one of the few countries in the region that have been accepted into the Pharmaceutical Inspection Cooperation/Scheme (PIC/S),“ he says. The country’s exports of pharmaceutical products received a boost, especially among the member countries, which include the EU, Australia and Canada with the admission of Malaysia as a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation/Scheme (PIC/S) in January 2002,

There is also growing demand for Malaysia’s expertise in production of halal pharmaceuticals and Malaysia’s halal certifications. Under the Healthcare National Key Economic Area (NKEA) sector, one of the key recommendations is to promote manufacturing of pharmaceuticals. New investments in the state-of-the-art technologies and compliance with international standards have enabled Malaysian companies to be strategic outsourcing partners for MNCs. Furthermore, Malaysia has established 27 Clinical Research Centres (CRC) to conduct clinical trials, clinical epidemiology and economic research, and manage complex medical databases.

According to Mr. Shankar, essentially these developments mean Malaysian pharmaceutical companies are more than capable of now only supplying products but also a wide-range of R&D and manufacturing services to the global pharmaceutical companies. At the CPhI, Malaysia is represented by some of its largest manufactures in the pharmaceutical industry. Details of the companies are as below:

1. Ethical, OTC and Food Supplements (all major therapeutic class and health supplements for children and adult).
2. OSD (tablet, capsule, & softgel)
3. Liquid
4. Cream

1. Ethical range covering all major therapeutic class
2. OSD (Tablet & Capsule)
3. Injectable
4. Liquid

1. Axcel – prescription medicine
2. Vaxcel – prescription injectable
3. Appeton – healthcare supplements

1. Continuous Ambulatory Peritoneal Dialysis (CAPD)
2. Metabolic solution bag for Intraveneous (IV)
3. Flexible medical solutions bags Irrigation and Veterinary

1. Traditional herbs supplements
2. Health care products
3. Toiletries
4. Cosmetics

Simvastatin (Health care product) & packaging services

Azithromycin (Medicine) & packaging services

Sommeil (Medicine)

1. Intravenous solutions
2. Irrigation solutions
3. Small volume products

Total logistic provider for sea, air and land.


MATRADE was established on March 1, 1993 as the external trade promotion arm of Malaysia’s Ministry of International Trade and Industry (MITI). Its functions are:
-To promote, assist and develop Malaysia’s external trade with particular emphasis on the export of manufactured and semi-manufactured products and services;
-To formulate and implement export marketing strategies and trade promotion activities to promote Malaysia’s export;
-To undertake commercial intelligence and market research and create a comprehensive database of information for the improvement and development of Malaysia’s trade;
-To organise training programmes to improve the international marketing skills of Malaysian exporters;
-To enhance and protect Malaysia’s international trade investment abroad; and
-To promote, facilitate and assist in the services areas related to trade.

NOTE TO EDITORS (not to be published)

For more information, please contact:
Ms.Janine Knorreck
Marketing Officer, MATRADE Frankfurt
Tel (Direct):015770226070
Web: www.matrade.gov.my

Media Agency for content and design

Uwe Fischer
Kruppstr. 72
40227 Düsseldorf